This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pamela Taulbee

Senior writer, health care, The Deal (Washington, D.C.)

Pamela Taulbee
By This Author:
« Back
Page 1 of 2

Pfizer Ponies Up to Develop Long-acting Growth Hormone

By Pamela Taulbee

Opko gains $295 million up front for global license to develop, market long-acting HGH.

11:38AM 12/16/14

Third Point's Daniel Loeb Tells Amgen it's Time to Break up

By Pamela Taulbee

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.

11:36AM 10/22/14

Changing hospital dynamic leads Becton Dickinson to buy CareFusion

By Pamela Taulbee

Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care.

02:28PM 10/06/14

Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B

By Pamela Taulbee

Perrigo gains women's health assets, Amag Pharmaceuticals buys Makena line in the transaction.

11:13AM 09/29/14

Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid

By Pamela Taulbee

The unsolicited bid comes a week after the Pennsylvania target announced a plant to cut 30% of its workforce.

11:50AM 09/17/14

Cognizant Expands Healthcare Information Technology With $2.7B Trizetto Buy

By Pamela Taulbee

Teaneck, N.J.-based information technology solutions company Cognizant Technology Solutions is adding the operations of TriZetto to create a fully integrated healthcare technology and operations leader.

11:08AM 09/15/14

Roche, InterMune a Strategic Play in Midst of Inversions

By Pamela Taulbee

As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.

09:19AM 08/27/14

Pfizer Bolsters Injectables by Buying InnoPharma

By Pamela Taulbee

Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.

10:17AM 07/17/14

St. Jude Medical Pays $200M for NeuroTherm

By Pamela Taulbee

Target produces radiofrequency ablation systems, boosting the buyer's pain management business.

09:44AM 07/15/14

Salix to Invert, Merging With Cosmo Pharma

By Pamela Taulbee

Building on the M&A trend for tax inversion deals, Salix Pharmaceuticals and Italy's Cosmo Pharmaceuticals plan to merge.

01:05PM 07/09/14

« Back
Page 1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs